Status:
TERMINATED
DNA Amplification in Blastocoel Fluid
Lead Sponsor:
Antalya IVF
Conditions:
Clinical Pregnancy
Embryo Implantation
Eligibility:
FEMALE
18-35 years
Phase:
NA
Brief Summary
Introduction: Although innovative procedural changes in frozen embryo transfer (FET) cycles have increased the implantation rate of blastocysts transferred significantly, blastocyst selection remains ...
Detailed Description
Introduction The goal of assisted reproductive technology (ART) is the delivery of a healthy singleton, with the treatment strategy in IVF having the best chance being the transfer of the single most ...
Eligibility Criteria
Inclusion
- Patients with female age 18≤35 years on the day of consultation (with the clinician projecting female age to be ≤35 on the day of oocyte retrieval).
- Patients who provide informed consent to participate in the trial and for the use of their anonymized data in research.
- Patients with ≤2 previous IVF treatments.
- Patients predicted to have single blastocyst transfers.
Exclusion
- Patients with female age \>35 years on the day of consultation.
- Female patients with insulin-dependent diabetes or non-insulin-dependent diabetes mellitus and female patients with gastrointestinal, cardiovascular, pulmonary, liver or kidney disease.
- Female patients with any contraindications or allergies to the drugs used in routine freeze-all-IVF.
- Patients undergoing conventional PGT-A (aneuploidy) or PGT-M (monogenic disorders)
- Patients with less than 5 2-PN zygotes on day 1 of embryo development will be excluded from randomization.
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2024
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04744844
Start Date
January 1 2022
End Date
January 31 2024
Last Update
February 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Antalya IVF
Antalya, Turkey (Türkiye), 07080